

# Symptom Clusters in Patients With Pancreatic Cancer Undergoing Surgical Resection: Part I

Sherry A. Burrell, PhD, RN, CNE, Theresa P. Yeo, PhD, MPH, AOCNP-BC®,  
Suzanne C. Smeltzer, EdD, RN, ANEF, FAAN, Benjamin E. Leiby, PhD, BA, Harish Lavu, MD,  
Eugene P. Kennedy, MD, and Charles J. Yeo, MD

**OBJECTIVES:** To describe patient-reported symptoms and symptom clusters in patients with pancreatic cancer (PC) undergoing surgical resection.

**SAMPLE & SETTING:** 143 patients with stage II PC undergoing surgical resection alone or with subsequent adjuvant chemoradiation or chemotherapy were recruited to participate in a nested, longitudinal, exploratory study through convenience sampling techniques from Thomas Jefferson University Hospital, a National Cancer Institute–designated cancer center.

**METHODS & VARIABLES:** The Functional Assessment in Cancer Therapy–Hepatobiliary questionnaire was used to assess 17 PC symptoms preoperatively and at three, six, and nine months postoperatively. Exploratory and confirmatory factor analyses were used to identify symptom clusters.

**RESULTS:** Fatigue, trouble sleeping, poor appetite, trouble digesting food, and weight loss were consistently reported as the most prevalent and severe symptoms. Sixteen distinct symptom clusters were identified within nine months of surgery. Four core symptom clusters persisted over time: affective, gastrointestinal, gustatory, and discomfort.

**IMPLICATIONS FOR NURSING:** Findings may be used to provide anticipatory patient and family guidance and to inform clinical assessments of symptoms and symptom clusters in this population.

**KEYWORDS** pancreatic cancer; symptom clusters; symptoms; surgical resection

**ONF, 45(4), E36–E52.**

**DOI** 10.1188/18.ONF.E36-E52

About 55,440 new cases of pancreatic cancer (PC) will be diagnosed in the United States in 2018 (Siegel, Miller, & Jemal, 2018). The five-year survival rate for all stages of PC in the United States has improved from 6% in 2013 to 8% in 2018 (Siegel et al., 2018; Siegel, Naishadham, & Jemal, 2013), and improved survival rates have made concerns about managing symptoms increasingly important. Some common concerns among patients with PC undergoing surgical resection include fatigue, pain, weakness, anxiety, depression, weight loss, insomnia, gastrointestinal disturbances, and symptoms of diabetes (Huang et al., 2000; Scheingraber, Scheingraber, Brauckhoff, & Dralle, 2005; Yeo et al., 2012). Evidence suggests that patients with cancer do not experience symptoms in isolation, but rather as multiple, concurrent symptoms or symptom clusters (SCs). Although the presence of SCs has been documented in many cancer types, little is known about SCs in patients with or without surgically resected PC.

SCs are defined as the simultaneous presence of two or more symptoms, which may or may not share etiology and are more strongly related to one another than other symptoms (Dodd, Miaskowski, & Lee, 2004; Kim, McGuire, Tulman, & Barsevick, 2005). SCs have been identified in individuals with lung (Franceschini, Jardim, Fernandes, Jamnik, & Santoro, 2013), ovarian (Huang et al., 2016), prostate (Dirksen, Belyea, Wong, & Epstein, 2016), and breast cancers (Starkweather et al., 2013) and are associated with decreased functional status (Kim, Barsevick, Beck, & Dudley, 2012), poor quality of life (QOL) (Franceschini et al., 2013), and reduced survival (Wikman, Johar, & Lagergren, 2014). Given the negative impact that SCs have on clinical outcomes, identifying and creating a classification of SCs and developing interventions to manage SCs have

become priorities for nursing research (Knobf et al., 2015).

SCs are a concern for patients with cancer and their family members, who must assume the daily responsibility of managing them. Understanding patients' perception of SCs over time is critical to ensure appropriate counseling, education, and symptom management (Dodd, Miaskowski, & Paul, 2001). Greater understanding of SCs may enable oncology professionals to tailor assessments to address SCs rather than individual symptoms. This may allow nursing professionals to not only more accurately identify and monitor multiple symptom concerns, but also to allow the most appropriate SC counseling, education, and symptom management strategies to be implemented at a particular point in time during the cancer trajectory (Nho, Reul Kim, & Nam, 2017). Through such applications, SC findings have the potential to have a positive effect on patient- and family-reported outcomes.

To date, only four researchers have examined SCs in patients with PC (see Table 1). In a longitudinal study, Reyes-Gibby et al. (2007) found that fatigue and anorexia formed a distinct SC over time in patients with unresectable, locally advanced PC who were undergoing chemoradiation. Noquez (2008) identified a SC of anxiety, depression, somatization, pain, and fatigue in patients with several cancer types, including PC. Laird et al. (2011) described a SC of fatigue, pain, and depression in patients with advanced gastrointestinal cancer, lung cancer, or PC. Yeo et al. (2012) explored SCs in patients with pancreatic and periampullary cancer (PPC) (i.e., ampullary, duodenal, and bile duct) three months postoperatively. The SCs identified were (a) fatigue, bodily pain, depression, weakness, and anxiety; (b) fatigue and shortness of breath; and (c) fatigue, diarrhea, pain, anxiety, and difficulty sleeping. Yeo et al. (2012) concluded that additional research was needed to determine the stability of SCs over time.

Research has not been conducted on SCs, longitudinally, in a cohort of patients with stage II PC undergoing surgical resection. The purpose of this article is to describe patient-reported symptom profiles and to identify SCs in patients with stage II PC prior to surgery and three, six, and nine months after surgery.

### Theoretical Framework

The conceptualization and design of the current study was guided by the Theory of Unpleasant Symptoms (TOUS) (Lenz, Pugh, Milligan, Gift, & Suppe, 1997). TOUS is comprised of three major components: (a) symptoms; (b) physiological, psychological, and situational factors that influence the perception of

symptoms; and (c) performance (i.e., the impact of symptoms on clinical outcomes). Although the concept of a SC is not explicitly included in the TOUS, the theory addresses the presence and interaction of multiple concurrent symptoms, which is congruent with the concept of SCs (Lenz & Pugh, 2008). The TOUS framework was used to guide the selection, definition, and operationalization of key study variables to gain a better understanding of symptoms and SCs experienced by patients with PC undergoing surgical resection throughout the perioperative period.

### Methods

#### Design, Sample, and Setting

This study was conducted as a nested, longitudinal, exploratory survey within a randomized, controlled trial (i.e., the parent study). The parent study (Lavu et al., 2015) evaluated the effectiveness of an intraoperative alcohol celiac nerve block (CNB) in reducing pain in patients with PPC undergoing surgery. Informed consent was obtained prior to parent study enrollment and after the purposes, methods, anticipated benefits, alternatives to participation, and potential risks were explained. A convenience sample of 485 patients participated in the parent study at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania.

The current study analyzed a sub-sample of patients from the parent study, specifically patients with American Joint Committee on Cancer (2009) stage IIa or IIb PC who underwent potentially curative surgery alone or with adjuvant therapy. Patients with stage I, III, or IV PPC, stage II periampullary cancer, and unresectable PC and those who did not return at least one preoperative and postoperative symptom questionnaire were excluded. The most common stage of PC in patients undergoing potentially curative resection is stage II (Yeo et al., 2012). In addition, researchers have found that patients with periampullary cancer have better survival than patients with PC (Sommerville et al., 2009), and stage of cancer is associated with increased number or severity of SCs (Karabulut, Erci, Ozer, & Ozdemir, 2010; Wang, O'Conner, Xu, & Liu, 2012), which has the potential to affect the disease trajectory and symptoms that cluster. Accordingly, the decision was made to ensure a homogenous sample by limiting participants to patients with stage II PC to enhance the clinical meaningfulness and use of SC findings from this study.

Experimental and placebo groups from the parent study were evaluated to determine (a) if the CNB was a confounding variable that could alter the pain-related SCs, and (b) if participants were equally distributed

**TABLE 1. Critical Analysis of the SC Literature in Patients With Pancreatic Cancer**

Study	Sample and Purpose	Research Design	SCs	Analysis
Laird et al., 2011	654 patients with advanced cancer with cachexia were studied to determine if pain, depression, and fatigue exist as a SC.	The study had a secondary, cross-sectional, descriptive research design. Regression analysis was used as the statistical method.	Pain, fatigue, and depression	<b>Strengths:</b> Patients were recruited from sites in several countries; large sample <b>Limitations:</b> The study contained a pooled sample of patients with advanced, heterogeneous cancer types experiencing cachexia with no attention to the intent (i.e., curative versus palliative) or type of treatment modality. In addition, patients were from two RCTs that included cachexia-related interventions, and no attention was paid to ensuring group similarity prior to analysis. No discussion occurred about how the interventions may have affected the symptoms that clustered in this study. The study had questionable operationalization of symptoms variables.
Noquez, 2008	523 patients with diverse cancer types were studied to examine the relationship between anxiety, depression, somatization, pain, and fatigue.	The study had a secondary cross-sectional, descriptive research design. Cluster analysis was used as the statistical method.	Anxiety, depression, somatization, pain, and fatigue; patients with pancreatic cancer, head and neck cancer, and lymphoma reported significantly higher intensity of this SC than patients with other cancer types.	<b>Strengths:</b> Strong use of theory for study conceptualization and design; large sample <b>Limitations:</b> Sample included heterogeneous cancer types without attention to stage of cancer or type of treatment. Another limitation was a lack of formal validity testing of the common problems checklist, one of the instruments used to collect symptom data in the study.
Reyes-Gibby et al., 2007	48 patients with pancreatic cancer (locally advanced, nonresectable, undergoing chemoradiation) were examined to describe the prevalence and co-occurrence of symptoms.	The study had a prospective, longitudinal, descriptive research design. Hierarchical cluster analysis was used as the statistical method.	Fatigue and anorexia (lack of appetite) formed a distinct symptom grouping or cluster before, during, and after treatment.	<b>Strengths:</b> The study was the first to examine SCs in patients with nonresectable pancreatic cancer. The study used a prospective, longitudinal approach to identify and examine changes in SCs over time. The study also used a multiple symptom assessment instrument to collect symptom data. <b>Limitations:</b> The study had a relatively small sample size, leading to a lack of sample diversity in terms of race, ethnicity, and socioeconomic status.
Yeo et al., 2012	102 patients with resected pancreas and periampullary cancers (stages I, II, and III) were examined to determine the impact of a home-based walking program on cancer-related fatigue, physical functioning, and quality of life.	The study was an RCT with cross-sectional SC analysis. Hierarchical cluster analysis was used as the statistical method.	SC 1: Fatigue, bodily pain, depression, weakness, and anxiety SC 2: Fatigue and shortness of breath SC 3: Pain, fatigue, diarrhea, anxiety, and trouble sleeping	<b>Strengths:</b> This study was the first to examine SCs in patients with PPC undergoing potentially curative surgical resection. The study used a prospective design for SC identification and an evidence-based checklist of common symptoms experienced by patients with pancreatic cancer. <b>Limitations:</b> The study had a lack of sample diversity. The study was not designed to assess how the walking intervention may have affected the symptoms that clustered.
PPC—pancreatic and periampullary cancer; RCT—randomized, controlled trial; SC—symptom cluster				

and could be combined into one sample for this study. No significant differences were observed among parent study groups on any clinical, demographic, or pain-related variables over time (all  $p > 0.05$ ). Therefore, the authors determined that the CNB was not a confounding variable and the study groups could be combined for this investigation. Institutional review board approval from Thomas Jefferson University Hospital and Villanova University was obtained specifically for this analysis as a nested study within the parent study.

Measures and Variables

Symptoms were assessed with the Functional Assessment in Cancer Therapy–Hepatobiliary (FACT-Hep) questionnaire (Heffernan et al., 2002), which measures 20 symptom concerns and QOL in patients with hepatobiliary cancers. The FACT-Hep instrument has been translated into more than 40 different languages, and it has been widely used to measure QOL and symptom concerns in patients with PC (Crippa et al., 2008; Okada et al., 2017; Serrano et al., 2014; Sun et al., 2008, 2016). The FACT-Hep has demonstrated good internal consistency (Cronbach alpha range = 0.72–0.94) and test-retest reliability (Spearman correlation range = 0.84–0.91) within one week of baseline assessment (Heffernan et al., 2002). All symptoms, except constipation and jaundice, are assessed on a five-point severity scale ranging from 0 (not at all) to 4 (very much). Constipation and jaundice are measured in terms of bother. Two FACT-Hep symptoms, fever and chills, were excluded because they are atypical in postoperative patients with PC (Huang et al., 2000; Yeo et al., 2012). Fatigue and abdominal pain are measured by two FACT-Hep items; therefore, the decision was made to collapse these variables into fatigue and abdominal pain/cramping variables by retaining the highest score recorded. Although three pain items are included on the FACT-Hep questionnaire (back pain, abdominal pain/cramping, and general pain), the authors excluded the general pain item because it is not specific to PC. Seventeen symptoms were included in the current study.

Data Collection

Symptom data were collected preoperatively (T1) and at three (T2), six (T3), and nine (T4) months postoperatively by trained personnel. Patients were mailed questionnaires at the appropriate times. If a questionnaire was not returned within two weeks, the patient was called and reminded to complete the

questionnaire and was given the option to complete the questionnaire by phone. Demographic and clinical data were obtained through a review of electronic health records. All data for this study were obtained from a review of the parent study folders.

Statistical Analysis

Data were analyzed using IBM SPSS Statistics, version 22.0; Mplus, version 6.0; and SAS, version 9.3 and 9.4. Descriptive statistics were used to describe demographic, clinical, and symptom prevalence and severity data. Exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) were used to identify SCs at each time point (Sass & Schmitt, 2010). In EFA, the number of factors is specified, but otherwise no structure is specified a priori. In CFA, results of the EFA are used to specify the number of factors/latent variables, as well as which observed symptoms are likely to be related to those variables. Symptoms that did not achieve at least 10% prevalence at each study time point were excluded from the EFA and CFA (Kim, Barsevick, Tulman, & McDermott, 2008).

TABLE 2. Sample Characteristics (N = 143)

Characteristic	$\bar{X}$	SD
Age (years)	67.3	10.4
Body mass index	25.54	4.35
Cigarette packs per year (n = 64)	31.7	26.5
Characteristic	n	%
Gender		
Male	82	57
Female	61	43
Race		
White	129	90
Black	8	6
Asian	5	4
Unknown	1	1
Ethnicity		
Non-Hispanic/non-Latino	134	94
Marital status		
Married or living with partner	107	75
Divorced, widowed, or separated	27	19
Never married or single	9	6
History of tobacco use		
Yes	85	59
No	58	41

Note. Because of rounding, percentages may not total 100.

Weighted least squares with orthogonal geomin rotation was used to conduct EFA (Bryant & Yarnold, 1995; Sass & Schmitt, 2010). The number of factors was determined using the chi-square test of model fit and Kaiser-Guttman rule (Bryant & Yarnold, 1995). To determine the reliability of identified SCs, a CFA using the Bayesian method (Muthén & Asparouhov, 2012) was conducted for each study time point using all patients with complete symptom data (n = 55). In the CFA models, loadings for symptoms related to factors from the EFA were assigned noninformative prior distributions with large variances (expressing uncertainty about the association of the symptom with the latent factors and allowing the data to drive the estimates), whereas symptoms thought to be unrelated to factors were given highly informative prior distributions centered at 0 (indicating no association) with little variance (expressing confidence that no association existed between the symptom and the factor).

Final factor models for each study time point were determined by the following criteria: (a) at least two symptoms with absolute factor loadings of 0.4 or greater (Kim et al., 2008) and (b) congruence between the EFA factor and CFA factor structures. Two or more symptoms with salient loadings on a factor were considered a SC. If the same symptom loaded on two factors, both symptoms were retained to enhance the clinical meaningfulness of findings.

### Sample Size Estimation

Subject-to-variable guidelines requiring at least five subjects for each variable were followed to determine the study sample size (Gorsuch, 1983). A sample size of 85 was deemed adequate to conduct a reliable factor analysis.

## Results

### Sample Characteristics

Survey response rates were 76% (n = 109) at three months, 64% (n = 92) at six months, and 62% (n = 89) at nine months postoperatively. The majority of participants were male, White (non-Hispanic/Latino), and married, with a mean age of 67.3 (SD = 10.4) years (see Table 2). Ninety-eight percent of patients (n = 120) reported one or more comorbid conditions. Twenty-two percent of patients reported having a mental health disorder (n = 31), most often including a past medical history of anxiety or depression. All patients underwent surgical resection, with the most common surgical procedure being the pylorus-preserving pancreaticoduodenectomy. Pathological histology confirmed the diagnosis of stage IIa (n = 28) or IIb

**TABLE 3. Medical Characteristics (N = 143)**

Characteristic	$\bar{X}$	SD
Number of comorbidities	4.38	2.36
Preoperative CEA levels (ng/ml)	5.71	9.41
Preoperative CA 19-9 levels (U/ml)	1,005.33	4,244.2
Characteristic	n	%
<b>Presence of comorbid conditions</b>		
Yes	140	98
No	3	2
<b>Comorbid conditions<sup>a</sup></b>		
Hypertension	85	59
Increased cholesterol or lipids	60	42
Gastroesophageal reflux	48	34
Diabetes mellitus	39	27
Arthritis	36	25
<b>History of mental health disorder</b>		
Yes	31	22
No	112	78
<b>Mental health disorder<sup>a</sup></b>		
Anxiety	14	45
Depression	19	61
Other	2	6
<b>Previous surgery</b>		
Yes	124	87
No	19	13
<b>Presenting symptoms</b>		
Yes	130	91
No	12	8
Unknown	1	1
<b>Symptoms<sup>a</sup></b>		
Jaundice	95	66
Abdominal pain	48	34
Weight loss	41	29
<b>Pancreatic cancer stage</b>		
IIa	28	20
IIb	115	80
<b>Primary surgical procedure</b>		
Pylorus-preserving pancreaticoduodenectomy	92	64
Classic pancreaticoduodenectomy	31	22
Distal pancreatectomy	17	12
Total pancreatectomy	3	2
<b>Secondary surgical procedure</b>		
Yes	119	83
No	24	17

*Continued on the next page*



**TABLE 3. Medical Characteristics (N = 143) (Continued)**

Characteristic	n	%
<b>Type of secondary surgical procedure<sup>a</sup></b>		
Splenectomy	25	19
Cholecystectomy	102	76
Hernia repair	6	4
Other procedure	2	2
<b>Neoadjuvant therapy</b>		
Yes	8	6
No	135	94
<b>Adjuvant therapy</b>		
Yes	117	82
No	26	18
<b>Presence of postoperative complications</b>		
Yes	54	38
No	89	62
<b>Postoperative complications</b>		
Delayed gastric emptying	12	22
Pancreatic fistula	9	17
Wound infection	9	17
Pneumonia	6	11
Abdominal abscess	6	11

<sup>a</sup>Participants could make more than one selection.  
CA—cancer antigen; CEA—carcinoembryonic antigen

(n = 115) pancreatic ductal adenocarcinoma in all patients. Following surgery, 82% of patients (n = 117) received adjuvant chemotherapy or combined therapy (see Table 3).

### Symptoms

Prevalence rates of all 17 symptoms were relatively high across all time points, with the exception of jaundice, which fell dramatically after surgery (see Table 4). Six symptoms were commonly reported at all study time points: fatigue, trouble sleeping, poor appetite, trouble digesting food, weight loss, and abdominal pain/cramping. Fatigue was the most consistently found symptom, with occurrence rates ranging from 92% (n = 131) at T1 to 90% (n = 83) at T3. The mean symptom severity scores were relatively mild to moderate, with all severity scores being below 2.15 (2 indicates “somewhat”) on a 0–4 scale (see Table 5). The five most severe symptoms reported at all study time points were fatigue, trouble sleeping, poor appetite, trouble digesting food, and weight loss. The most severe symptom was fatigue, which ranged

from a mean score of 1.92 (SD = 1.13) at T1 to a mean score of 2.14 (SD = 1.17) at T2. The mean number of concurrent symptoms was 9.62 (SD = 3.35) at T1, 8.75 (SD = 3.68) at T2, 8.66 (SD = 3.45) at T3, and 8.98 (SD = 3.55) at T4.

### Preoperative Symptom Clusters

Seventeen symptoms were included in the EFA and CFA models preoperatively (see Table 6). A five-factor solution was a good fit with the EFA ( $\chi^2_{61} = 62.7$ ;  $p = 0.42$ ) and CFA models. Trouble sleeping and diarrhea did not cluster (load of 0.4 or greater) at T1.

**Pain–gastrointestinal symptom cluster:** In the EFA and CFA ( $p < 0.05$ ) models, nausea, trouble digesting food, poor appetite, back pain, constipation, and abdominal pain/cramping loaded (clustered) on factor 1 at T1.

**Mood symptom cluster:** Anxiety and depression loaded on preoperative factor 2 in both the EFA and CFA ( $p < 0.05$ ) models.

**Digestive problems symptom cluster:** In the EFA and CFA ( $p < 0.05$ ) models, loss of bowel control and trouble digesting food loaded on factor 3 at T1.

**Fatigue–nutritional problems symptom cluster:** In the EFA model, weight loss, fatigue, itching, change in taste, and dry mouth loaded on preoperative factor 4. In the CFA model, weight loss, fatigue, change in taste, and dry mouth significantly loaded on factor 4 ( $p < 0.05$ ). Given the variability in loading of itching between the models, itching was determined to be unstable and was not included in final factor 4 structure at T1.

**Jaundice symptom cluster:** Nausea and jaundice loaded on preoperative factor 5 in the EFA model. In the CFA model, nausea, jaundice, itching, fatigue, change in taste, and dry mouth loaded with  $p < 0.05$ . Only symptoms that loaded on both models were retained; therefore, only jaundice and itching were included in the final factor 5 structure at T1.

### Postoperative Symptom Clusters at Three Months

Sixteen symptoms were included in the EFA and CFA models at three, six, and nine months postoperatively (jaundice was excluded because it did not meet the 10% prevalence criteria). At 3 months after surgery, a four-factor solution was a good fit with data in the EFA ( $\chi^2_{62} = 74.2$ ;  $p = 0.14$ ) and CFA models. Constipation did not cluster (load at 0.4 or greater) at T2 (see Table 7).

**Mood–pain–anorexia–fatigue symptom cluster:** In the EFA and CFA ( $p < 0.05$ ) models, nausea, depression, anxiety, poor appetite, back pain, fatigue, and abdominal pain/cramping loaded on factor 1 at T2.

**Insomnia-digestive problems symptom cluster:**

Trouble sleeping, loss of bowel control, and trouble digesting food loaded on factor 2 at T2 in the EFA and CFA ( $p < 0.05$ ) models.

**Gastrointestinal sickness symptom cluster:**

In the EFA model, nausea, diarrhea and itching loaded on factor 3 at T2. These same symptoms loaded in the CFA model; however, significance was not achieved ( $p = 0.1$ ), suggesting this clustering of symptoms is less reliable.

**Nutritional problems symptom cluster:**

Weight loss, itching, change in taste, and dry mouth loaded on factor 4 at T2 in the EFA and CFA ( $p < 0.05$ ) models.

**Postoperative Symptom Clusters at Six Months**

As shown in Table 8, 16 symptoms were included in the EFA and CFA models at 6 months after surgery. A four-factor solution was a good fit with data in the EFA ( $\chi^2_{62} = 66.7$ ;  $p = 0.32$ ) and CFA models. Nausea did not cluster at T3.

**Mood-pain-insomnia-gastrointestinal symptom**

**cluster:** Depression, anxiety, trouble sleeping, back pain, and constipation loaded on factor 1 in the EFA and CFA models at T3. Although depression, anxiety, trouble sleeping, and constipation all loaded ( $p < 0.05$ ), back pain failed to achieve significance in the CFA model ( $p = 0.1$ ). This suggests that the inclusion of back pain as a component of SCs is less reliable.

**Bowel-digestive problems symptom cluster:**

Loss of bowel control, trouble digesting food, and diarrhea loaded on factor 2 at T3 in the EFA and CFA ( $p < 0.05$ ) models.

**Fatigue-anorexia-nutritional problems symptom**

**cluster:** Fatigue, poor appetite, weight loss, change in taste, and dry mouth loaded on factor 3 at T3 in the EFA and CFA ( $p < 0.05$ ) models.

**Pain-itching symptom cluster:**

In the EFA and CFA ( $p < 0.05$ ) models, itching, abdominal pain/cramping, and back pain loaded on factor 4 at T3.

**TABLE 4. Symptom Prevalence Over Time**

Symptom	T1 (N = 143)		T2 (N = 109)		T3 (N = 92)		T4 (N = 89)	
	n	%	n	%	n	%	n	%
Fatigue	131	92	99	91	83	90	86	91
Anxiety	119	84	62	57	54	59	44	50
Trouble sleeping	105	75	76	70	67	74	68	77
Poor appetite	103	73	70	64	62	68	53	60
Weight loss	101	72	61	57	55	61	53	60
Depression	97	68	66	61	55	61	54	61
Trouble digesting food	88	62	72	66	65	72	67	76
Abdominal pain or cramping	87	61	69	64	52	57	57	65
Dry mouth	77	54	64	59	51	56	50	57
Back pain	76	54	43	39	30	33	38	43
Loss of bowel control	65	46	67	62	53	58	53	61
Change in taste	62	43	62	57	52	57	49	56
Itching	60	42	30	28	20	22	25	28
Diarrhea	53	37	42	39	41	45	49	56
Jaundice (bother)	53	37	4	4	2	2	5	6
Nausea	52	37	35	32	28	30	27	30
Constipation (bother)	46	33	39	36	27	30	27	31
T1—preoperative; T2—3 months postoperative; T3—6 months postoperative; T4—9 months postoperative								

### Postoperative Symptom Clusters at Nine Months

Sixteen symptoms were included in the EFA and CFA models at nine months after surgery (see Table 9). A four-factor solution was a good fit with data in the EFA ( $\chi^2_{62} = 69.9$ ;  $p = 0.23$ ) and CFA models. Only one symptom (itching) loaded on factor 4 in this model; therefore, it did not meet the definition of a SC. Poor appetite failed to cluster at T4.

**Mood–insomnia–pain–nausea symptom cluster:** In the EFA, depression, anxiety, nausea, trouble sleeping, constipation, back pain, and abdominal pain/cramping loaded on factor 1 at T4. In the CFA model, only depression, anxiety, nausea, trouble sleeping, back pain, and abdominal pain/cramping significantly loaded ( $p < 0.05$ ). Constipation failed to load in the CFA model and was not included in final factor 1 structure.

**Digestive–weight loss–bowel problems symptom cluster:** In the EFA and CFA ( $p < 0.05$ ) models, loss of

bowel control, trouble digesting food, diarrhea, constipation, and weight loss loaded on factor 2 at T4.

**Fatigue–pain–nutritional problems symptom cluster:** In the EFA and CFA ( $p < 0.05$ ) models, fatigue, change in taste, dry mouth, back pain, and constipation loaded on factor 3 at T4.

### Core Symptom Clusters

Although the symptoms that clustered over time were not identical, four consistent core SCs were identified. The affective core SC included the symptoms of anxiety and depression, which consistently clustered at each study time point. The gastrointestinal core SC was present at all study time points and included the symptoms of trouble digesting food and the loss of bowel control. The gustatory core SC, which included a change in taste and dry mouth, also consistently clustered at all study time points. The symptoms of nausea, back pain, and abdominal pain/cramping

**TABLE 5. Symptom Severity Over Time**

Symptom	T1 (N = 143)		T2 (N = 109)		T3 (N = 92)		T4 (N = 89)	
	$\bar{X}$	SD	$\bar{X}$	SD	$\bar{X}$	SD	$\bar{X}$	SD
Fatigue	1.92	1.13	2.14	1.17	2.02	1.16	2	1.05
Anxiety	1.73	1.21	0.94	1	0.85	0.89	0.74	0.9
Trouble sleeping	1.6	1.26	1.27	1.11	1.24	1.05	1.41	1.13
Poor appetite	1.54	1.3	1.25	1.26	1.19	1.08	1.01	1.23
Weight loss	1.51	1.29	1.10	1.28	1.09	1.12	1.16	1.25
Depression	1.27	1.1	1.02	1.02	0.98	0.94	1.03	1.02
Trouble digesting food	1.26	1.26	1.16	1.15	1.12	0.99	1.4	1.13
Abdominal pain or cramping	1.26	1.25	1.1	1.1	0.88	0.99	1.28	1.23
Itching	1.08	1.48	0.41	0.8	0.31	0.71	0.44	0.83
Dry mouth	1.05	1.22	1.18	1.28	0.86	0.96	1.05	1.12
Back pain	1.04	1.23	0.61	0.93	0.59	1.05	0.78	1.19
Loss of bowel control	0.94	1.27	1.23	1.27	1.07	1.17	1.17	1.23
Change in taste	0.87	1.2	1.1	1.22	1.02	1.12	1.09	1.18
Jaundice (bother)	0.86	1.33	0.06	0.3	0.05	0.43	0.07	0.3
Nausea	0.67	1.04	0.49	0.82	0.52	0.92	0.47	0.84
Constipation (bother)	0.64	1.09	0.63	1.01	0.48	0.87	0.51	0.95
Diarrhea	0.63	1.01	0.74	1.16	0.80	1.1	1.08	1.23

T1—preoperative; T2—3 months postoperative; T3—6 months postoperative; T4—9 months postoperative

**Note.** Scores range from 0 (not at all) to 4 (very much).



demonstrated a relatively consistent relationship by clustering together at T1, T2, and T4, and were termed the discomfort core SC.

## Discussion

### Symptoms

The prevalence of the 17 symptoms experienced by patients with PC prior to and after surgical resection was relatively high, except for jaundice, which fell below 10% occurrence after surgery. Fatigue had the highest prevalence, which is consistent with the often-reported finding of it being the most common and distressing symptom for patients with advanced cancers (Butt et al., 2008) and specifically in a cohort of patients with PPC (Yeo et al., 2012). The most prevalent symptoms in this sample varied somewhat over time, but fatigue, trouble sleeping, poor appetite,

trouble digesting food, and weight loss were consistently the most prevalent and severe symptoms at all four time points. Overall, the mean symptom severity was mild to moderate, with all severity scores below 2.15 on a 0–4 scale. These findings suggest that patients with PC undergoing surgical resection experience a wide variety of symptoms concerns, although the most prevalent symptoms tend to be similar throughout the perioperative period.

Patients with PC reported a median of 10 concurrent symptoms preoperatively and 9 concurrent symptoms postoperatively at T2, T3, and T4. Eighty-two percent of patients (n = 117) received postresection adjuvant therapy. Although recovery from surgery typically occurs within six months, the side effects of neoadjuvant and adjuvant treatment may account for the persistent concurrent symptoms. Similarly, Chang,

**TABLE 6. EFA (N = 143) and CFA (N = 55) Preoperative Factor Structures**

Symptom	Factor 1		Factor 2		Factor 3		Factor 4		Factor 5	
	EFA	CFA	EFA	CFA	EFA	CFA	EFA	CFA	EFA	CFA
Nausea	0.82	0.85*	–	–	–	–	–	–	0.7	0.43*
Depression	–	–	1.21	2.55*	–	–	–	–	–	–
Anxiety	–	–	0.51	0.81*	–	–	–	–	–	–
Trouble sleeping	–	–	–	–	–	–	–	–	–	–
Weight loss	–	–	–	–	–	–	0.46	0.58*	–	–
Loss of bowel control	–	–	–	–	0.92	1.42*	–	–	–	–
Trouble digesting food	0.57	1.75*	–	–	0.74	2.68*	–	–	–	–
Diarrhea	–	–	–	–	–	–	–	–	–	–
Poor appetite	0.49	0.85*	–	–	–	–	–	–	–	–
Back pain	0.5	0.59*	–	–	–	–	–	–	–	–
Constipation (bother)	0.42	0.54*	–	–	–	–	–	–	–	–
Fatigue	–	–	–	–	–	–	0.64	1.27*	–	0.61*
Itching	–	–	–	–	–	–	0.56	–	–	1.05*
Change in taste	–	–	–	–	–	–	0.68	0.59*	–	0.67*
Dry mouth	–	–	–	–	–	–	0.73	0.81*	–	0.68*
Abdominal pain or cramping	0.52	0.97*	–	–	–	–	–	–	–	–
Jaundice (bother)	–	–	–	–	–	–	–	–	0.67	0.77*

\* p < 0.05

CFA—confirmatory factor analysis; EFA—exploratory factor analysis

**Note.** Factor loading ≥ 0.4, chi-square test of model fit =  $\chi^2_{61} = 62.7$ , p = 0.42

Hwang, Feuerman, and Kasimis (2000) surveyed 240 patients with cancer undergoing active treatment and found that they experienced a median of eight concurrent symptoms.

### Symptom Clusters

The findings from the current study provide the first data-driven evidence of 16 distinct SCs in surgically resected patients with PC within nine months of surgery. Although the SCs identified over time were not identical, four core SCs persisted over time: the affective, gastrointestinal, gustatory, and discomfort SCs.

**Affective core symptom cluster:** Anxiety and depression clustered at each study time point. A distinct anxiety and depression SC has not been previously identified in this population, although anxiety and depression have been long reported by patients with PC. Green and Austin (1993) examined 20 studies (n = 21) and found that 48% (n = 10) of patients

with PC experienced anxiety and 71% (n = 15) experienced symptoms of depression. Although anxiety and depression are common affective reactions to cancer throughout the disease trajectory, patients with PC have been found to experience some of the highest levels of anxiety and depression when compared to patients with other cancer types (Carlson et al., 2004; Noquez, 2008; Zabora, BrintzenhofeSzoc, Curbow, Hooker, & Piantadosi, 2001). Therefore, it was expected that these symptoms would cluster in surgically resected patients with PC. The reason that high levels of anxiety and depression occur in patients with PC remains largely unknown, but some evidence suggests that pathologic changes associated with the tumor itself may account for high rates of some affective reactions, such as depression, in this population (Musselman et al., 2001).

The high rates of anxiety and depression found in previous studies (Carlson et al., 2004; Noquez, 2008;

**TABLE 7. EFA (N = 109) and CFA (N = 55) Three-Month Factor Structures**

Symptom	Factor 1		Factor 2		Factor 3		Factor 4	
	EFA	CFA	EFA	CFA	EFA	CFA	EFA	CFA
Nausea	0.61	0.88*	–	–	0.4	0.5	–	–
Depression	0.79	0.87*	–	–	–	–	–	–
Anxiety	0.9	0.95*	–	–	–	–	–	–
Trouble sleeping	–	–	0.47	0.57*	–	–	–	–
Weight loss	–	–	–	–	–	–	0.47	0.56*
Loss of bowel control	–	–	0.83	1.69*	–	–	–	–
Trouble digesting food	–	–	0.83	2.39*	–	–	–	–
Diarrhea	–	–	–	–	0.68	1.51	–	–
Poor appetite	0.41	0.85*	–	–	–	–	–	–
Back pain	0.74	0.89*	–	–	–	–	–	–
Constipation (bother)	–	–	–	–	–	–	–	–
Fatigue	0.58	0.9*	–	–	–	–	–	–
Itching	–	–	–	–	–0.48	–0.42	0.62	0.53*
Change in taste	–	–	–	–	–	–	0.55	1.28*
Dry mouth	–	–	–	–	–	–	0.56	0.99*
Abdominal pain or cramping	0.43	0.71*	–	–	–	–	–	–

\* p < 0.05

CFA—confirmatory factor analysis; EFA—exploratory factor analysis

**Note.** Factor loading  $\geq 0.4$ , chi-square test of model fit =  $\chi^2_{61} = 74.2$ , p = 0.14

Zabora et al., 2001) are consistent with the current findings that 84% (n = 119) of patients reported anxiety and 68% (n = 97) reported depression at T1. SCs of anxiety and depression have also been reported in patients with breast (Bender, Ergün, Rosenzweig, Cohen, & Sereika, 2005), brain (Gleason et al., 2007), and advanced cancers (Cheung, Le, Gagliese, & Zimmerman, 2011; Chow et al., 2008). In the PC literature, anxiety and depression were found to cluster with several other symptoms. Noquez (2008) found anxiety and depression to be clustered with pain, somatization, and fatigue in a large sample of patients with mixed cancer types, including PC. Fatigue, bodily pain, anxiety, depression, and weakness clustered in a study of postoperative patients with PPC (Yeo et al., 2012).

**Gastrointestinal core symptom cluster:** Trouble digesting food and the loss of bowel control clustered at all study time points. The symptoms of trouble

digesting food and loss of bowel control have not been previously reported to cluster in the SC literature. Digestive problems, including the inability to digest food accompanied by diarrhea (steatorrhea) that may be associated with incontinence is likely related to pancreatic enzyme insufficiency (Coleman, 2010), a common physiologic occurrence in patients with PC before and after potential curative surgical resection.

Preoperatively, pancreatic enzyme insufficiency occurs when the pancreas fails to produce enough digestive enzymes as a result of malignant changes or an obstruction of the biliary or pancreatic ducts that prevent digestive enzymes from reaching the duodenum to allow for proper digestion of carbohydrates, proteins, and fats (Coleman, 2010; Hodgins, 2011). Trouble digesting food and the loss of bowel control are also concerns after resection, which may be related to (a) removal of a portion of the pancreas, (b) resection of a portion of the stomach, or (c) resection of part

**TABLE 8. EFA (N = 92) and CFA (N = 55) Six-Month Factor Structures**

Symptom	Factor 1		Factor 2		Factor 3		Factor 4	
	EFA	CFA	EFA	CFA	EFA	CFA	EFA	CFA
Nausea	-	-	-	-	-	-	-	-
Depression	0.82	2*	-	-	-	-	-	-
Anxiety	0.71	0.99*	-	-	-	-	-	-
Trouble sleeping	0.54	0.75*	-	-	-	-	-	-
Weight loss	-	-	-	-	0.49	0.6*	-	-
Loss of bowel control	-	-	0.98	2.66*	-	-	-	-
Trouble digesting food	-	-	0.69	1.04*	-	-	-	-
Diarrhea	-	-	0.58	0.83*	-	-	-	-
Poor appetite	-	-	-	-	0.86	1.02*	-	-
Back pain	0.54	0.48	-	-	-	-	0.63	1.03*
Constipation (bother)	0.5	0.57*	-	-	-	-	-	-
Fatigue	-	-	-	-	0.58	0.94*	-	-
Itching	-	-	-	-	-	-	0.65	0.57*
Change in taste	-	-	-	-	0.69	1.3*	-	-
Dry mouth	-	-	-	-	0.6	1.06*	-	-
Abdominal pain or cramping	-	-	-	-	-	-	0.54	1.35*
* p < 0.05								
CFA—confirmatory factor analysis; EFA—exploratory factor analysis								
<b>Note.</b> Factor loading $\geq 0.4$ , chi-square test of model fit = $\chi^2_{61} = 66.7$ , p = 0.32								

of the duodenum, which may reduce mucosal surface area in the duodenum that is needed for absorptive processes (Mackay, Hayes, & Yeo, 2006; Sohn & Yeo, 2002). In addition, these gastrointestinal symptoms may also be caused by neoadjuvant chemotherapy or postoperative adjuvant therapy (Coleman, 2010).

**Gustatory core symptom cluster:** Changes in taste and dry mouth consistently clustered at all four time points. Although this SC has not been previously identified in patients with PC, the relationship among these symptoms has been established in the literature. Neoadjuvant and adjuvant chemotherapy and/or radiation therapy have been associated with a wide range of gastrointestinal symptoms in patients with PC, including nausea, vomiting, changes in taste or smell, loss of appetite, and bowel changes (Coleman, 2010), which may account for the clustering of dry mouth and changes in taste in this study. Dry mouth is one of the most common side effects of

many pain medications prescribed during the perioperative period. An association between the symptoms of changes in taste and dry mouth has also been identified as a part of a larger SC and was found in patients with breast (Roiland & Heidrich, 2011), head and neck (Xiao et al., 2012), esophageal (Wikman et al., 2014), and advanced cancers (Aktas, Walsh, & Rybicki, 2012).

**Discomfort core symptom cluster:** Nausea, back pain, and abdominal pain/cramping demonstrated a relatively consistent relationship by clustering at T1, T2, and T4. Although this clustering of symptoms was not previously reported in PC populations, a relationship between pain and poor appetite has been reported as part of a larger SC in patients with lung cancer (Brown, Cooley, Chernecky, & Sarna, 2011), patients undergoing adjuvant therapy (Skerman, Yates, & Battistutta, 2012), and patients undergoing stem cell transplantation (Jarden, Nelausen,

**TABLE 9. EFA (N = 89) and CFA (N = 55) Nine-Month Factor Structures**

Symptom	Factor 1		Factor 2		Factor 3		Factor 4	
	EFA	CFA	EFA	CFA	EFA	CFA	EFA	CFA
Nausea	0.5	0.82*	–	–	–	–	–	–
Depression	0.7	1.01*	–	–	–	–	–	–
Anxiety	0.83	1.37*	–	–	–	–	–	–
Trouble sleeping	0.62	0.8*	–	–	–	–	–	–
Weight loss	–	–	0.4	0.45*	–	–	–	–
Loss of bowel control	–	–	0.92	2.21*	–	–	–	–
Trouble digesting food	–	–	0.78	1.52*	–	–	–	–
Diarrhea	–	–	0.53	0.7*	–	–	–	–
Poor appetite	–	–	–	–	–	–	–	–
Back pain	0.57	0.62*	–	–	0.4	0.81*	–	–
Constipation (bother)	0.4	–	–0.4	–0.51*	0.43	0.8*	–	–
Fatigue	–	–	–	–	0.68	1.11*	–	–
Itching	–	–	–	–	–	–	1.06	1.05*
Change in taste	–	–	–	–	0.7	0.83*	–	–
Dry mouth	–	–	–	–	0.56	0.91*	–	–
Abdominal pain or cramping	0.52	0.76*	–	–	–	–	–	–

\*  $p < 0.05$

CFA—confirmatory factor analysis; EFA—exploratory factor analysis

**Note.** Factor loading  $\geq 0.4$ , chi-square test of model fit =  $\chi^2_{61} = 69.9$ ,  $p = 0.23$

Hovgaard, Boesen, & Adamsen, 2009). Pain associated with PC is often described by patients as a dull, intermittent, and diffuse pain located in the abdomen or back (Hodgins, 2011). In the current investigation, 57% (n = 52) of patients reported abdominal pain/cramping and 33% (n = 30) of patients reported back pain throughout the perioperative period. Nausea is a common PC symptom that is associated with alterations in gastrointestinal functioning from the tumor itself, surgical resection, and neoadjuvant/adjuvant therapy (Coleman, 2010; Hodgins, 2011; Mackay et al., 2006; Sohn & Yeo, 2002). Therefore, it was not surprising that abdominal and/or back pain would cluster with nausea in patients with PC undergoing surgical resection.

### Limitations

Several limitations exist for this study. Convenience sampling of patients from a single, high-volume PC center and inclusion of a small homogenous sample with limited racial and ethnic diversity limit the generalizability of the authors' findings. In addition, the current sample included a cohort of patients with stage II PC, the majority of whom underwent surgical resection via a pylorus-preserving pancreaticoduodenectomy. A systematic review suggested that patients undergoing a potentially curative resection via a classic pancreaticoduodenectomy may experience significantly higher rates of delayed gastric emptying postoperatively when compared to patients undergoing a pylorus-preserving pancreaticoduodenectomy (Hüttner et al., 2016), which may have affected how associated symptoms, such as nausea and vomiting, clustered in this study. Similarly, although depression and anxiety are common occurrences in patients with PC (Carlson et al., 2004; Noquez, 2008; Zabora et al., 2001) and have been found to be present months (as many as 42 months) prior to the time of diagnosis (Fras, Litin, & Pearson, 1967), 22% of patients with PC in this study (n = 31) reported a history of a mental health disorder, the vast majority of whom reported a mood disorder, including 61% depression (n = 19) and 45% anxiety (n = 14) which, to reiterate, may have affected the clustering of symptoms.

The use of the FACT-Hep instrument and failure to capture specific data related to neoadjuvant and adjuvant treatments are also limitations of this study. Although the FACT-Hep tool is a valid and reliable symptom and QOL measure, it was not designed to conduct a multidimensional symptom assessment. The FACT-Hep tool measured most symptoms in terms of severity; however, two symptoms were

measured in terms of bother (jaundice and constipation). This may have affected the symptoms that clustered in this analysis. Neoadjuvant and adjuvant treatment data were self-reported by patients, and details regarding specific chemotherapy agents, radiation therapy treatment, and the timing of adjuvant therapy were only sporadically reported, which precluded more detailed data analysis in this study.

### Implications for Nursing

The TOUS (Lenz et al., 1997) served as a helpful framework to guide this study. The first step toward effective symptom management is to gain a thorough understanding of the symptoms or SCs (Dodd et al., 2001). Findings from this study provide valuable insight into the presence and severity of symptoms and SCs experienced by surgically resected patients with PC preoperatively and as many as nine months postoperatively, which has not been previously reported. In addition, the TOUS would be a helpful framework to guide future interprofessional SC research in patients with PC. More specifically, the TOUS provides an ideal method to conceptualize (i.e., variable selection and identification of relationships to examine) and conduct research focused on gaining a better understanding of the factors that influence the presence or severity of SCs and consequences that SCs may have on important performance outcomes, such as functional status, QOL, and survival.

### Implications for Nursing Practice

Results of this study may be used in oncology nursing practice to increase understanding of symptoms and SCs experienced by patients with PC undergoing surgical resection, which may inform assessments and monitoring, counseling and education, and the anticipatory guidance provided to patients and their families about what symptoms to expect after PC surgery. The findings may be used to target assessments to address SCs, rather than individual symptoms, which is consistent with the experience of postoperative patients with PC. The variability in the symptoms that clustered over time in the current study also underscores the need to complete regular assessments to capture changes in SCs.

Knowledge of the differences in distinct SC patterns may be used to not only enhance the accuracy of SC assessments and monitoring to allow for the earlier identification of existing SCs, but also to predict what symptoms are likely to cluster in patients with PC undergoing surgical resection throughout

the perioperative period. More accurate and regular SC assessments and monitoring may allow oncology nurses to implement earlier counseling, education, and symptom management strategies as indicated throughout the cancer trajectory (Nho et al., 2017) to mitigate the presence or severity of SCs or prevent the occurrence of SCs in their entirety. As such, SC findings from this study have the potential to have a positive impact on important patient- and family-reported outcomes.

Current oncology practice may also use several specific core SC findings to enhance the nursing and collaborative care provided to patients with PC during the perioperative period. For example, the affective core SC was present throughout the perioperative period, suggesting that oncology nursing professionals must be vigilant in assessing patients for the presence of anxiety and depression. It is well documented in the literature that high levels of anxiety and depression have been associated with negative impact on patients' adherence to cancer treatment and clinical outcomes, such as QOL and even survival (Arrieta et al., 2013; Frick, Tyroller, & Panzer, 2007; Vodermaier, Lucas, Linden, & Olson, 2017). Given the detrimental impact that anxiety and depression may have on clinical outcomes, oncology nurses must advocate for patients with PC to ensure they are receiving appropriate evidence-based symptom management strategies and referrals to mental health professionals, as indicated.

Similarly, the gastrointestinal core SC, consisting of trouble digesting food and loss of bowel control, is likely associated with preoperative or postoperative pancreatic enzyme insufficiency, and is currently managed in clinical practice by the use of oral pancreatic enzyme replacement with meals and snacks (Coleman, 2010). For optimal management, oral pancreatic enzyme supplements are titrated until stools achieve a desirable consistency, which requires patient and family education and counseling. Oncology nursing professionals are in a prime role to teach patients and families about the proper use of pancreatic enzyme supplements, coordinate with the oncology team to ensure proper enzyme replacement titration, and advocate for referrals to a registered dietitian when more intensive nutritional management is required.

### Implications for Nursing Research

Larger, multicenter studies with greater racial and ethnic diversity are warranted to confirm the presence of the SCs identified in this study in patients

---

### KNOWLEDGE TRANSLATION

- Sixteen distinct symptom clusters (SCs) and four core SCs were identified within nine months of pancreatic cancer resection.
  - Findings may be used to provide anticipatory patient and family guidance and inform clinical assessments of symptoms and SCs in this population.
  - Additional research should focus on confirming the presence of the four core SCs that persisted throughout the current study: affective, gastrointestinal, gustatory, and discomfort.
- 

with stage II PC and to generalize findings to patients with other stages of PC. Given the large number of SCs identified in this study, researchers should focus their future attention on confirming the presence of the four core SCs that persisted over time: affective, gastrointestinal, gustatory, and discomfort. Future research should be conducted using a systematic, regular interval approach to SC assessments using a well-validated and reliable comprehensive symptom assessment tool to ensure the capture of cancer and treatment-related symptoms in a consistent manner, with attention to important symptom qualities (i.e., timing, severity, interference, and distress). In addition, several symptoms loaded on two different factors (clustered with two symptom groupings) over time in the EFA and CFA models. Although these findings may be a product of the relatively small sample size, such findings may also suggest that there is a shared underlying causative mechanism that warrants additional study.

### Conclusion

This study is the first to explore symptoms and identify SCs over time in patients with stage II PC undergoing surgical resection. Sixteen SCs were identified within the first nine months of surgery alone or along with adjuvant therapy. Although the symptoms that clustered were not identical at all times, four persistent core SCs were identified. Findings from this study may be used to provide anticipatory guidance and inform clinical assessments of symptoms and SCs in this population. Additional research is warranted to (a) confirm the presence of the identified SCs in large, multicenter studies with adequate racial and ethnic diversity; (b) generalize the identified SCs to patients with all stages of PC undergoing surgery; and (c) identify underlying biologic mechanisms that contribute to the development of SCs in this population.



**Sherry A. Burrell, PhD, RN, CNE**, is an assistant professor in the M. Louise Fitzpatrick College of Nursing at Villanova University in Pennsylvania; **Theresa P. Yeo, PhD, MPH, AOCNP-BC®**, is co-director of the Jefferson Pancreas Tumor Registry, a nurse practitioner in the Department of Surgery at Thomas Jefferson University Hospital, and an adjunct professor in the Jefferson College of Nursing at Thomas Jefferson University in Philadelphia, PA; **Suzanne C. Smeltzer, EdD, RN, ANEF, FAAN**, is a professor in the M. Louise Fitzpatrick College of Nursing and Director of the Center for Nursing Research at Villanova University; **Benjamin E. Leiby, PhD, BA**, is an associate professor and director of the Division of Biostatistics at Thomas Jefferson University; **Harish Lavu, MD**, is the section chief of hepatopancreatobiliary surgery in the Department of Surgery at Thomas Jefferson University Hospital and an associate professor in the Sidney Kimmel Medical College at Thomas Jefferson University; **Eugene P. Kennedy, MD**, is the chief medical officer at NewLink Genetics in Philadelphia; and **Charles J. Yeo, MD**, is a professor in the Sidney Kimmel Medical College at Thomas Jefferson University and chair of the Department of Surgery at Thomas Jefferson University Hospital. Burrell can be reached at sherry.burrell@villanova.edu, with copy to ONFEditor@ons.org. (Submitted November 2017. Accepted February 8, 2018.)

This research was funded by a doctoral degree scholarship in cancer nursing awarded to Burrell from the American Cancer Society (DSCN 11-195-01). Burrell has previously received honorarium from the Oncology Nursing Society and Wolters Kluwer for review activities. Leiby has previously consulted for Bayer HealthCare.

Burrell, T. Yeo, and Lavu completed the data collection. Leiby provided statistical support. Burrell, T. Yeo, Leiby, Lavu, and C. Yeo provided the analysis. All authors contributed to the conceptualization and design and the manuscript preparation.

## REFERENCES

- Aktas, A., Walsh, D., & Rybicki, L. (2012). Symptom clusters and prognosis in advanced cancer. *Supportive Care in Cancer*, 20, 2837–2843. <https://doi.org/10.1007/s00520-012-1408-9>
- American Joint Committee on Cancer. (2009). *Pancreas cancer staging* (7th ed.). Retrieved from <https://cancerstaging.org/references-tools/quickreferences/Documents/PancreasSmall.pdf>
- Arrieta, O., Angulo, L.P., Núñez-Valencia, C., Dorantes-Gallareta, Y., Macedo, E.O., Martínez-López, D., . . . Oñate-Ocaña, L.F. (2013). Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. *Annals of Surgical Oncology*, 20, 1941–1948. <https://doi.org/10.1245/s10434-012-2793-5>
- Bender, C.M., Ergün, F.S., Rosenzweig, M.Q., Cohen, S.M., & Sereika, S.M. (2005). Symptom clusters in breast cancer across 3 phases of the disease. *Cancer Nursing*, 28, 219–225.
- Brown, J.K., Cooley, M.E., Chernecky, C., & Sarna, L. (2011). A symptom cluster and sentinel symptom experienced by women with lung cancer [Online exclusive]. *Oncology Nursing Forum*, 38, E425–E435. <https://doi.org/10.1188/11.ONF.E425-E435>
- Bryant, F.B., & Yarnold, P.R. (1995). Principal-components analysis and exploratory and confirmatory factor analysis. In L.G. Grimm and P.R. Yarnold (Eds.), *Reading and understanding multivariate statistics* (pp. 99–136). Washington, DC: American Psychological Association.
- Butt, Z., Rosenbloom, S.K., Abernethy, A.P., Beaumont, J.L., Paul, D., Hampton, D., . . . Cella, D. (2008). Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. *Journal of the National Comprehensive Cancer Network*, 6, 448–455.
- Carlson, L.E., Angen, M., Cullum, J., Goodey, E., Koopmans, J., Lamont, L., . . . Bultz, B.D. (2004). High levels of untreated distress and fatigue in cancer patients. *British Journal of Cancer*, 90, 2297–2304. <https://doi.org/10.1038/sj.bjc.6601887>
- Chang, V.T., Hwang, S.S., Feuerman, M., & Kasimis, B.S. (2000). Symptom and quality of life survey of medical oncology patients at a Veterans Affairs medical center: A role for symptom assessment. *Cancer*, 88, 1175–1183.
- Cheung, W.Y., Le, L.W., Gagliese, L., & Zimmerman, C. (2011). Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer. *Supportive Care in Cancer*, 19, 417–423. <https://doi.org/10.1007/s00520-010-0865-2>
- Chow, E., Fan, G., Hadi, S., Wong, J., Kirou-Mauro, A., & Filipczak, L. (2008). Symptom clusters in cancer patients with brain metastases. *Clinical Oncology*, 20, 76–82. <https://doi.org/10.1016/j.clon.2007.09.007>
- Coleman, J. (2010). Diarrhea. In C.G. Brown (Ed.), *A guide to oncology symptom management* (pp. 173–195). Pittsburgh, PA: Oncology Nursing Society.
- Crippa, S., Dominquez, I., Rodriquez, J.R., Razo, O., Thayer, S.P., Ryan, D.P., . . . Fernández-del Castillo, C. (2008). Quality of life in pancreatic cancer: Analysis by stage and treatment. *Journal of Gastrointestinal Surgery*, 12, 783–793. <https://doi.org/10.1007/s11605-007-0391-9>
- Dirksen, S.R., Belyea, M.J., Wong, W., & Epstein, D.R. (2016). Transitions in symptom cluster subgroups among men undergoing prostate cancer radiation therapy. *Cancer Nursing*, 39, 3–11. <https://doi.org/10.1097/NCC.000000000000236>
- Dodd, M.J., Miaskowski, C., & Lee, K.A. (2004). Occurrence of symptom clusters. *Journal of the National Cancer Institute Monographs*, 32, 76–78. <https://doi.org/10.1093/jncimonographs/lgh008>
- Dodd, M.J., Miaskowski, C., & Paul, S.M. (2001). Symptom clusters and their effect on the functional status of patients with cancer. *Oncology Nursing Forum*, 28, 465–470.
- Franceschini, J., Jardim, J.R., Fernandes, A.L., Jamnik, S., & Santoro, I.L. (2013). Relationship between the magnitude of symptoms and the quality of life: A cluster analysis of lung

- cancer patients in Brazil. *Jornal Brasileiro de Pneumologia*, 39, 23–31.
- Fras, I.L., Litin, E.M., & Pearson, J.S. (1967). Comparison of psychiatric symptoms in carcinoma of the pancreas with those in some other intra-abdominal neoplasms. *American Journal of Psychiatry*, 123, 1553–1562. <https://doi.org/10.1176/ajp.123.12.1553>
- Frick, E., Tyroller, M., & Panzer, M. (2007). Anxiety, depression and quality of life of cancer patients undergoing radiation therapy: A cross-sectional study in a community hospital outpatient centre. *European Journal of Cancer Care*, 16, 130–136. <https://doi.org/10.1111/j.1365-2354.2006.00720.x>
- Gleason, J.F., Jr., Case, D., Rapp, S.R., Ip, E., Naughton, M., Butler, J.M., Jr., . . . Shaw, E.G. (2007). Symptom clusters in patients with newly-diagnosed brain tumors. *Journal of Supportive Oncology*, 5, 427–433.
- Gorsuch, R.L. (1983). *Factor analysis* (2nd ed.). Manwah, NJ: Lawrence Erlbaum Associates.
- Green, A.I., & Austin, C.P. (1993). Psychopathology of pancreatic cancer. A psychobiologic probe. *Psychosomatics*, 34, 208–221. [https://doi.org/10.1016/S0033-3182\(93\)71882-4](https://doi.org/10.1016/S0033-3182(93)71882-4)
- Heffernan, N., Cella, D., Webster, K., Odom, L., Martone, M., Passik, S., . . . Blumgart, L. (2002). Measuring health-related quality of life in patients with hepatobiliary cancers: The functional assessment of cancer therapy-hepatobiliary questionnaire. *Journal of Clinical Oncology*, 20, 2229–2239. <https://doi.org/10.1200/JCO.2002.07.093>
- Hodgins, M.B. (2011). Pancreatic cancer. In C.H. Yarbrow, D. Wujcik, & B.H. Gopal (Eds.). *Cancer nursing: Principles and practice* (7th ed., pp. 1581–1609). Sudbury, MA: Jones and Bartlett.
- Huang, J., Gu, L., Zhang, L., Lu, X., Zhuang, W., & Yang Y. (2016). Symptom clusters in ovarian cancer patients with chemotherapy after surgery: A longitudinal survey. *Cancer Nursing*, 39, 106–116. <https://doi.org/10.1097/NCC.0000000000000252>
- Huang, J.J., Yeo, C.J., Sohn, T.A., Lillemo, K.D., Sauter, P.K., Coleman, J., . . . Cameron, J.L. (2000). Quality of life and outcomes after pancreaticoduodenectomy. *Annals of Surgery*, 231, 890–898.
- Hüttner, F.J., Fitzmaurice, C., Schwarzer, G., Seiler, C.M., Antes, G., Büchler, M.W., & Diener, M.K. (2016). Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. *Cochrane Database of Systematic Reviews*, CD006053. <https://doi.org/10.1002/14651858.CD006053.pub6>
- Jarden, M., Nelausen, K., Hovgaard, D., Boesen, E., & Adamsen, L. (2009). The effect of a multimodal intervention on treatment-related symptoms in patients undergoing hematopoietic stem cell transplantation: A randomized controlled trial. *Journal of Pain and Symptom Management*, 38, 174–190. <https://doi.org/10.1016/j.jpainsymman.2008.09.005>
- Karabulut, N., Erci, B., Ozer, N., & Ozdemir, S. (2010). Symptom clusters and experiences of patients with cancer. *Journal of Advanced Nursing*, 66, 1011–1021. <https://doi.org/10.1111/j.1365-2648.2009.05254.x>
- Kim, H.J., Barsevick, A.M., Beck, S.L., & Dudley, W. (2012). Clinical subgroups of a psychoneurologic symptom cluster in women receiving treatment for breast cancer: A secondary analysis [Online exclusive]. *Oncology Nursing Forum*, 39, E20–E30. <https://doi.org/10.1188/12.ONF.E20-E30>
- Kim, H.J., Barsevick, A.M., Tulman, L., & McDermott, P.A. (2008). Treatment-related symptom clusters in breast cancer: A secondary analysis. *Journal of Pain and Symptom Management*, 36, 468–479. <https://doi.org/10.1016/j.jpainsymman.2007.11.011>
- Kim, H.J., McGuire, D.B., Tulman, L., & Barsevick, A.M. (2005). Symptom clusters: Concept analysis and clinical implications for cancer nursing. *Cancer Nursing*, 28, 270–282.
- Knobf, M.T., Cooley, M.E., Duffy, S., Doorenbos, A., Eaton, L., Given, B., . . . Mallory, G. (2015). The 2014–2018 Oncology Nursing Society research agenda. *Oncology Nursing Forum*, 42, 450–465. <https://doi.org/10.1188/15.ONF.450-465>
- Laird, B.J., Scott, A.C., Colvin, L.A., McKeon, A.L., Murray, G.D., Fearon, K.C., & Fallon, M.T. (2011). Pain, depression, and fatigue as a symptom cluster in advanced cancer. *Journal of Pain and Symptom Management*, 42, 1–11. <https://doi.org/10.1016/j.jpainsymman.2010.10.261>
- Lavu, H., Lengel, H.B., Sell, N.M., Baiocco, J.A., Kennedy, E.P., Yeo, T.P., . . . Yeo, C.J. (2015). A prospective, randomized, double-blind, placebo controlled trial on the efficacy of ethanol celiac plexus neurolysis in patients with operable pancreatic and periampullary adenocarcinoma. *Journal of the American College of Surgeons*, 220, 497–508. <https://doi.org/10.1016/j.jamcollsurg.2014.12.013>
- Lenz, E.R., & Pugh, L.C. (2008). Theory of unpleasant symptoms. In M.J. Smith and P.R. Liehr (Eds.), *Middle range theory for nursing* (2th ed., pp. 159–182). New York, NY: Springer.
- Lenz, E.R., Pugh, L.C., Milligan, R.A., Gift, A.G., & Suppe, F. (1997). The middle-range theory of unpleasant symptoms: An update. *Advances in Nursing Science*, 19(3), 14–27.
- Mackay, S., Hayes, T., & Yeo, A. (2006). Management of gastric cancer. *Australian Family Physician*, 35, 208–211.
- Musselman, D.L., Miller, A.H., Porter, M.R., Manatunga, A., Gao, F., Penna, S., . . . Nemeroff, C.B. (2001). Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: Preliminary findings. *American Journal of Psychiatry*, 158, 1252–1257. <https://doi.org/10.1176/appi.ajp.158.8.1252>
- Muthén, B., & Asparouhov, T. (2012). Bayesian structural equation modeling: A more flexible representation of substantive theory. *Psychological Methods*, 17, 313–335. <https://doi.org/10.1037/a0026802>
- Nho, J.H., Reul Kim, S., & Nam, J.H. (2017). Symptom clustering and quality of life in patients with ovarian cancer undergoing chemotherapy. *European Journal of Oncology Nursing*, 30, 8–14. <https://doi.org/10.1016/j.ejon.2017.07.007>
- Noquez, A.E. (2008). *Cancer-related symptom clusters* (Doctoral

- dissertation). Retrieved from ProQuest Dissertations and Theses Global. (Publication No. AAT 3314979).
- Okada, K.I., Shimokawa, T., Hirono, S., Kawai, M., Sho, M., Satoi, S., . . . Yamaue, H. (2017). Effect of neoadjuvant nab-paclitaxel plus gemcitabine therapy on overall survival in patients with borderline resectable pancreatic cancer: A prospective multicenter phase II trial (NAC-GA trial). *Oncology*, 93, 343–346. <https://doi.org/10.1159/000478660>
- Reyes-Gibby, C.C., Chan, W., Abbruzzese, J.L., Xiong, H.Q., Ho, L., Evans, D.B., . . . Crane, C. (2007). Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. *Journal of Pain and Symptom Management*, 34, 244–252. <https://doi.org/10.1016/j.jpainsymman.2006.11.007>
- Roiland, R.A., & Heidrich, S.M. (2011). Symptom clusters and quality of life in older adult breast cancer survivors. *Oncology Nursing Forum*, 38, 672–680. <https://doi.org/10.1188/11.ONF.672-680>
- Sass, D.A., & Schmitt, T.A. (2010). A comparative investigation of rotation criteria within exploratory factor analysis. *Multivariate Behavioral Research*, 45, 73–103. <https://doi.org/10.1080/002073170903504810>
- Scheingraber, S., Scheingraber, T., Brauckhoff, M., & Dralle, H. (2005). Comparison between a general and a disease-specific health-related quality-of-life questionnaire in patients after pancreatic surgery. *Journal of Hepato-Biliary-Pancreatic Surgery*, 12, 290–297. <https://doi.org/10.1007/s00534-005-0973-4>
- Serrano, P.E., Herman, J.M., Griffith, K.A., Zalupski, M.M., Kim, E.J., Bekaii-Saab, T.S., . . . Wei, A.C. (2014). Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma. *International Journal of Radiation Oncology, Biology, Physics*, 90, 270–277. <https://doi.org/10.1016/j.ijrobp.2014.05.053>
- Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. *CA: A Cancer Journal for Clinicians*, 63, 11–30. <https://doi.org/10.3322/caac.21166>
- Siegel, R.L., Miller, K.D., & Jemal, A. (2018). Cancer statistics, 2018. *CA: A Cancer Journal for Clinicians*, 68, 7–30. <https://doi.org/10.3322/caac.21442>
- Skerman, H.M., Yates, P.M., & Battistutta, D. (2012). Cancer-related symptom clusters for symptom management in outpatients commencing adjuvant chemotherapy, at 6 months, and 12 months. *Supportive Care in Cancer*, 20, 95–105. <https://doi.org/10.1007/s00520-010-1070-z>
- Sohn, T., & Yeo, C.J. (2002). Pancreatic and periampullary carcinoma (nonendocrine). In G.D. Zuidema and C.J. Yeo (Eds.), *Shackelford's surgery of the alimentary tract*. (5th ed., pp. 63–87). Philadelphia, PA: W.B. Saunders Company.
- Sommerville, C.A., Limongelli, P., Pai, M., Ahmad, R., Stamp, G., Habib, N.A., . . . Jiao, L.R. (2009). Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: An analysis of clinicopathological factors. *Journal of Surgical Oncology*, 100, 651–656. <https://doi.org/10.1002/jso.21390>
- Starkweather, A.R., Lyon, D.E., Elswick, R.K., Jr., Montpetit, A., Conley, Y., & McCain, N.L. (2013). Symptom cluster research in women with breast cancer: A comparison of three subgrouping techniques. *Advances in Breast Cancer Research*, 2(4), 107–114. <https://doi.org/10.4236/abcr.2013.24018>
- Sun, V., Ferrell, B., Juarez, G., Wagman, L.D., Yen, Y., & Chung, V. (2008). Symptom concerns and quality of life in hepatobiliary cancers [Online exclusive]. *Oncology Nursing Forum*, 35, E45–E52. <https://doi.org/10.1188/08.ONF.E45-E52>
- Sun, V., Ruel, N., Chung, V., Singh, G., Leong, L., Fakih, M., . . . Ferrell, B. (2016). Pilot study of an interdisciplinary supportive care planning intervention in pancreatic cancer. *Supportive Care in Cancer*, 24, 3417–3424. <https://doi.org/10.1007/s00520-016-3155-9>
- Vodermaier, A., Lucas, S., Linden, W., & Olson, R. (2017). Anxiety after diagnosis predicts lung cancer-specific and overall survival in patients with stage III non-small cell lung cancer: A population-based cohort study. *Journal of Pain and Symptom Management*, 53, 1057–1065. <https://doi.org/10.1016/j.jpainsymman.2016.12.338>
- Wang, Y., O'Conner, M., Xu, Y., & Liu, X. (2012). Symptom clusters in Chinese patients with primary liver cancer [Online exclusive]. *Oncology Nursing Forum*, 39, E468–E479. <https://doi.org/10.1188/12.ONF.E468-E479>
- Wikman, A., Johar, A., & Lagergren, P. (2014). Presence of symptom clusters in surgically treated patients with esophageal cancer: Implications for survival. *Cancer*, 120, 286–293
- Xiao, C., Hanlon, A., Zhang, Q., Ang, K., Rosenthal, D.I., Nguyen-Tan, P.F., . . . Bruner, D.W. (2012). Symptom clusters in patients with head and neck cancer receiving concurrent chemoradiation. *Oral Oncology*, 49, 360–366.
- Yeo, T.P., Burrell, S.A., Sauter, P.K., Kennedy, E.P., Lavu, H., Leiby, B.E., & Yeo, C.J. (2012). A progressive postresection walking program significantly improves fatigue and health-related quality of life in pancreas and periampullary cancer patients. *Journal of the American College of Surgeons*, 214, 463–475. <https://doi.org/10.1016/j.jamcollsurg.2011.12.017>
- Zabora, J., BrintzenhofeSzoc, K., Curbow, B., Hooker, C., & Piantadosi, S. (2001). The prevalence of psychosocial distress by cancer site. *Psycho-Oncology*, 10, 19–28.